Cognitive impairment has been described in patients 7 months after SARS-CoV-2 infection [69] and increased markers of neurodegenerative processes involving total serum tau, phosphorylated tau, and neurofilament light chain have been detected in patients with COVID-19 [70]. This evidence concerns the gene MAPT and COVID-19.